DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
compose your message
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Imara Reports Favorable Preclinical and Phase 1 Data on IMR-687 in Sickle Cell Disease
Imara Inc. today announced it will report additional preclinical and Phase 1 clinical data from the company’s lead compound, IMR-687, a once-daily, oral therapy designed to address the underlying pathology of sickle cell disease (SCD). In preclinical studies, IMR-687’s mechanism of action was shown to positively impact both red and white blood cell pathologies associated with the disease. The company has previously reported the ability of IMR-687 to induce fetal hemoglobin (HbF) in murine and human cells at ASH in 2017. Importantly, the data from a recent Phase 1 clinical trial in healthy volunteers demonstrated IMR-687 to be safe and well-tolerated at the target dose that exceeded the effective doses in cell and animal models of SCD, thereby clearing a path to a Phase 2 study in adult patients with SCD. The new data will be presented at the 6th Annual Sickle Cell Therapeutics Conference in New York.
education & researchPatient Reported Outcomes and Adherence to Hydroxyurea in Adolescents and Young Adults With Sickle Cell Disease: A F...Background: SCD-related complications r...
education & researchSickle Cell Disease: Managing PainCurrently, sickle cell disease has no wi...
news & eventsCalimmune Expands Lentiviral Gene Therapy Pipeline Through License of Sickle Cell Disease Therapeutic CandidateLicense of Gamma-Globin from Cincinnati ...
news & eventsMarijuana use common in sickle cell patients, highlighting need for more research, study showsMany sickle cell disease (SCD)...
videos & visuals4 Transition Stages of Sickle Cell Disease and Tips for Each Stagehttps://www.onescdvoice.com/wp-content/u...
news & eventsCTX001 Continues to Show Promise in Severe SCDA single dose of CTX001, an experimental...
Community CenterLiving With Sickle Cell Disease: One Person’s Story of Pain and Prejudice and Their Hopes for a Stem Cell TherapyMy name is Marissa Cors, I have sickle c...
send a message
Don’t forget to join the oneSCDvoice community!
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.